These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34483943)

  • 1. Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study.
    Armentaro G; D'Arrigo G; Magurno M; Toscani AF; Condoleo V; Miceli S; Cassano V; Maio R; Arturi F; Tripepi G; Sesti G; Sciacqua A
    Front Pharmacol; 2021; 12():733475. PubMed ID: 34483943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study.
    Armentaro G; D'Arrigo G; Miceli S; Cassano V; Perticone M; Maio R; Marra AM; Arturi F; Cittadini A; Tripepi G; Sesti G; Sciacqua A
    Front Physiol; 2022; 13():897109. PubMed ID: 35694400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea.
    Pelaia C; Armentaro G; Volpentesta M; Mancuso L; Miceli S; Caroleo B; Perticone M; Maio R; Arturi F; Imbalzano E; Andreozzi F; Perticone F; Sesti G; Sciacqua A
    Front Cardiovasc Med; 2022; 9():861663. PubMed ID: 35449875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fraction: The "Hemodynamic Recovery".
    Romano G; Vitale G; Ajello L; Agnese V; Bellavia D; Caccamo G; Corrado E; Di Gesaro G; Falletta C; La Franca E; Minà C; Storniolo SA; Sarullo FM; Clemenza F
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis.
    Armentaro G; Condoleo V; Pelaia C; Cassano V; Miceli S; Maio R; Salzano A; Pelle MC; Perticone M; Succurro E; Arturi F; Andreozzi F; Sesti G; Sciacqua A
    Intern Emerg Med; 2023 Jan; 18(1):113-125. PubMed ID: 36478322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study.
    De Vecchis R; Paccone A; Di Maio M
    Cardiol Res; 2019 Oct; 10(5):293-302. PubMed ID: 31636797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
    Lelonek M; Wiśniowska-Śmiałek S; Rubiś P; Nowakowska I; Pawlak A
    Adv Clin Exp Med; 2021 Jan; 30(1):67-75. PubMed ID: 33529509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population.
    Dattilo G; Laterra G; Licordari R; Parisi F; Pistelli L; Colarusso L; Zappia L; Vaccaro V; Demurtas E; Allegra M; Crea P; Di Bella G; Signorelli SS; Aspromonte N; Imbalzano E; Correale M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
    Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
    Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
    Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
    Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
    Mazzetti S; Scifo C; Abete R; Margonato D; Chioffi M; Rossi J; Pisani M; Passafaro G; Grillo M; Poggio D; Mortara A
    ESC Heart Fail; 2020 Jun; 7(3):964-972. PubMed ID: 32233080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study.
    Zeymer U; Groves R; Hupfer S
    Herz; 2024 Apr; ():. PubMed ID: 38656397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Pericas P; Mas-Lladó C; Ramis-Barceló MF; Valadrón I; Noris Mora M; Pasamar Márquez L; González Colino R; Forteza Albertí JF; Peral Disdier V; Rossello X
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):167-175. PubMed ID: 33599965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences.
    Castrichini M; Manca P; Nuzzi V; Barbati G; De Luca A; Korcova R; Stolfo D; Lenarda AD; Merlo M; Sinagra G
    J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32218231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction.
    Fang CC; Jao YTFN
    Acta Cardiol Sin; 2023 Mar; 39(2):297-308. PubMed ID: 36911550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.